Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.D·J·劳里...
Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclos
Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the ...
Inhibitors of Bruton's tyrosine kinase and methods of their use The present disclosure is directed to compounds of Formula (I) and methods of their use and preparation, as well as compositions comprising compounds of Fo... N Arora,GM Bacani,JK Barbay,... 被引量: 0发表: 2022年 Discovery...
The compounds provided can be used as selective irreversible bruton's tyrosine kinase (Btk) inhibitors and is further useful to treat inflammatory, auto immune diseases associated with aberrant B-cell proliferation such as RA (rheumatoid arthritis) and cancers. This invention also provided the ...
Bruton's tyrosine kinase (BTK) is a non-receptor protein kinase that plays a crucial role in various biological processes, including immune system function and cancer development. Therefore, inhibition of BTK has been proposed as a therapeutic strategy for various complex diseases. In this study, ...
Leukemia www.nature.com/leu ARTICLE OPEN LYMPHOMA Inhibitors of Bcl-2 and Bruton's tyrosine kinase synergize to abrogate diffuse large B-cell lymphoma growth in vitro and in orthotopic xenotransplantation models Katrin Bertram1, Peter John Leary1,2, Christophe Boudesco1, Jonas Fullin1, Kristin ...
Bruton's tyrosine kinase (BTK), an intracellular NRTK, plays a crucial role in B-cell antigen receptor (BCR) signaling pathway. The application of BTK inhibitors, such as ibrutinib, acalabrutinib, and zanubrutinib, is considered as a breakthrough in B-cell-related hematological malignancies ...
Targeted therapy with Bruton tyrosine kinase (BTK) inhibitors have revolutionized the treatment of patients with various B-cell malignancies. BTK inhibitors such as ibrutinib, zanubrutinib, orelabrutinib, and acalabrutinib have shown good clinical effica
BPG致力于知识的发现和传播 Bruton’s tyrosine kinase inhibitors in primary central nervous system lymphoma: New hopes on the horizon Leonardo S Lino-Silva, Sabrina B Martínez-Villavicencio, Luisa Fernanda Rivera-Moncada Leonardo S Lino-Silva, Sabrina B Martínez-Villavicencio, Luisa Fernanda Rivera-...